Cabaletta Bio Stock Forecasts

Cabaletta Bio, a clinical-stage biotech company, develops cancer treatments. The company's lead product, CAB-201, is an anti-CD19 CAR T cell therapy for relapsed/refractory B-cell lymphomas. Cabaletta Bio aims to improve upon existing CAR T cell therapies by using a lower dose and shorter treatment duration. The company's technology also enables the use of a patient's own T cells, reducing the risk of toxicity and immunogenicity. Cabaletta Bio has completed a Phase 1 trial and is planning a Phase 2 trial to evaluate the safety and efficacy of CAB-201.